Mechanisms of acquired resistance to three purine analogues, 2-chloro-2'-deoxyadenosine
(cladribine, CdA), 9-beta-D-arabinofuranosyl-2-fluoroadenine (fludarabine, Fara-A),
and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (clofarabine, CAFdA) were investigated
in a human T-lymphoblastic leukemia cell line (CCRF-CEM). These analogues are pro-drugs
and must be activated by deoxycytidine kinase (dCK). The CdA and CAFdA resistant cell
lines exhibited increased resistance to the other nucleoside analogues activated by
dCK. This was also the case for the Fara-A resistant cells, except that they were
sensitive to CAFdA and guanosine analogues. The CdA and CAFdA resistant cells displayed
a deficiency in dCK activity (to <5%) while the Fara-A resistant cells showed only
a minor reduction of dCK activity (20% reduction). The activity of high K(m) 5'-nucleotidase
(5'-NT) (cN-II) using IMP as substrate, was 2-fold elevated in the resistant cell
lines. The amount of the small subunit R2 of ribonucleotide reductase (RR) was higher
in the Fara-A resistant cells, which translated into a higher RR activity, while CdA
and CAFdA cells had decreased activity compared to the parental cells. Expression
of the recently identified RR subunit, p53R2 full-size protein, in CAFdA cells was
low compared to parental cells, but a protein of lower molecular weight was detected
in CdA and CAFdA cells. Co-incubation of Fara-A with the RR inhibitor 3,4-dihydroxybenzohydroxamic
acid (didox) enhanced cytotoxicity in the Fara-A resistant cells by a factors of 20.
Exposure of the cells to the nucleoside analogues studied here also caused structural
and numerical instability of the chromosomes; the most profound changes were recorded
for CAFdA cells, as demonstrated by SKY and CGH analysis. We conclude that down-regulation
of dCK in cells resistant to CdA and CAFdA and increased activity of RR in cells resistant
to Fara-A contribute to resistance.